ORGS - オ―ジェネシス (Orgenesis Inc.) オ―ジェネシス

 ORGSのチャート


 ORGSの企業情報

symbol ORGS
会社名 Orgenesis Inc (オ―ジェネシス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company's subsidiary MaSTherCell SA which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine Autologous Insulin Producing (AIP) cells into clinical development.   オ―ジェネシスは米国のバイオ医薬品企業。臨床段階で、糖尿病のトランス分化技術の開発・商業化に従事する。肝臓からの細胞発達の変化を促し、糖尿病1型患者の膵臓のベ―タ細胞のようなインスリン生産細胞に分化する技術に基づく細胞治療が含まれる。また、他の細胞治療に焦点を当てる事業も展開する。本社所在地はメリ―ランド州ジャ―マンタウン。   Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCare Platform is comprised of three enabling components: a pipeline of licensedPOCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. Orgenesis identifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies.
本社所在地 20271 Goldenrod Lane Germantown MD 20876 USA
代表者氏名 Vered Caplan ヴェードキャプラン
代表者役職名 Chairman of the Board Chief Executive Officer President; Chief Executive Officer of Orgenesis Maryland Inc.
電話番号 +1 480-659-6404
設立年月日 39600
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 103人
url www.orgenesis.com
nasdaq_url https://www.nasdaq.com/symbol/orgs
adr_tso
EBITDA EBITDA(百万ドル) -5.41200
終値(lastsale) 6.63
時価総額(marketcap) 96594850.17
時価総額 時価総額(百万ドル) 96.85145
売上高 売上高(百万ドル) 16.23000
企業価値(EV) 企業価値(EV)(百万ドル) 82.92945
当期純利益 当期純利益(百万ドル) -14.15100
決算概要 決算概要 BRIEF: For the nine months ended 31 August 2018 Orgenesis Inc revenues increased 91% to $12.9M. Net loss applicable to common stockholders increased 26% to $13.3M. Revenues reflect CDMO segment increase from $4.7M to $23.5M CTB segment increase from $0K to $83K. Higher net loss reflects CTB segment loss increase from $6M to $14M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.11 to -$1.07.

 ORGSのテクニカル分析


 ORGSのニュース

   Orgenesis Achieves Multiple Ranpirnase Development Milestones  2021/07/06 11:00:00 Intrado Digital Media
FDA Pre-IND consultation completed; submission of phase 2 trial of Ranpirnase for anogenital warts on schedule
   Orgenesis Stock Appears To Be Modestly Overvalued  2021/06/23 04:00:09 GuruFocus
Related Stocks: ORGS ,
   Is Orgenesis Inc. (ORGS) A Good Stock To Buy?  2021/06/15 19:23:03 Insider Monkey
   Orgenesis says enrollment is underway for a Phase 2 rotator cuff repair study of its Tissue Genesis Icellator  2021/06/10 12:54:00 Proactive Investors
Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) announced that enrollment has commenced for a clinical trial using the companys Tissue Genesis Icellator in rotator cuff repair surgeries at the Hospital for Special Surgery (HSS) in New York. The Phase 2 trial, supported by the National Stem Cell Foundation and an Orthopedic Research and Education Foundation grant, will evaluate the safety and efficacy of autologous stromal and vascular fraction cells (SVF) that are injected after surgical rotator cuff repair. The Tissue Genesis Icellator will be utilized for the cell recovery process, the company said. Orgenesis acquired the Icellator technology in October to supplement its offering of POCare technology systems. It functions as an automated, functionally closed system for the recovery of SVF from autologous adipose (read: fat) tissue. It is designed for use at the point of care, the company said. READ: Orgenesis reports four-fold increase in revenue in 1Q as it continues to grow its POCare strategy Nine of an eventual 56 total patients have been enrolled so far, the company said.
   Orgenesis announces use of the Tissue Genesis Icellator® in a Hospital for Special Surgery clinical study for rotator cuff repair  2021/06/10 11:00:00 Intrado Digital Media
Investigator-initiated, randomized, placebo-controlled, phase 2 trial to evaluate autologous stromal and vascular fraction cell (SVF) injections after rotator cuff surgery Investigator-initiated, randomized, placebo-controlled, phase 2 trial to evaluate autologous stromal and vascular fraction cell (SVF) injections after rotator cuff surgery
   Is Orgenesis Inc. (ORGS) A Good Stock To Buy?  2021/06/15 19:23:03 Insider Monkey
   Orgenesis says enrollment is underway for a Phase 2 rotator cuff repair study of its Tissue Genesis Icellator  2021/06/10 12:54:00 Proactive Investors
Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) announced that enrollment has commenced for a clinical trial using the companys Tissue Genesis Icellator in rotator cuff repair surgeries at the Hospital for Special Surgery (HSS) in New York. The Phase 2 trial, supported by the National Stem Cell Foundation and an Orthopedic Research and Education Foundation grant, will evaluate the safety and efficacy of autologous stromal and vascular fraction cells (SVF) that are injected after surgical rotator cuff repair. The Tissue Genesis Icellator will be utilized for the cell recovery process, the company said. Orgenesis acquired the Icellator technology in October to supplement its offering of POCare technology systems. It functions as an automated, functionally closed system for the recovery of SVF from autologous adipose (read: fat) tissue. It is designed for use at the point of care, the company said. READ: Orgenesis reports four-fold increase in revenue in 1Q as it continues to grow its POCare strategy Nine of an eventual 56 total patients have been enrolled so far, the company said.
   Orgenesis announces use of the Tissue Genesis Icellator® in a Hospital for Special Surgery clinical study for rotator cuff repair  2021/06/10 11:00:00 Intrado Digital Media
Investigator-initiated, randomized, placebo-controlled, phase 2 trial to evaluate autologous stromal and vascular fraction cell (SVF) injections after rotator cuff surgery Investigator-initiated, randomized, placebo-controlled, phase 2 trial to evaluate autologous stromal and vascular fraction cell (SVF) injections after rotator cuff surgery
   Orgenesis announces use of the Tissue Genesis Icellator in a Hospital for Special Surgery clinical study for rotator cuff repair  2021/06/10 11:00:00 Wallstreet:Online
Investigator-initiated, randomized, placebo-controlled, phase 2 trial to evaluate autologous stromal and vascular fraction cell (SVF) injections after rotator cuff surgery GERMANTOWN, Md., June 10, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (Orgenesis or the Company), a global biotech company working to unlock the full potential of cell and gene therapies, announces
   Orgenesis to Present at the Summer Solstice Conference - Best Ideas from the Buy-Side on June 2nd  2021/06/01 11:30:00 GlobeNewswire
GERMANTOWN, Md., June 01, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (Orgenesis or the Company), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will be presenting at the Summer Solstice Conference, hosted by The MicroCap Rodeo, being held virtually on June 1 st June 4 th , 2021.
   Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of Cell and Gene Therapies in Collaboration with Dong-a University Hospital and Cure Therapeutics in South Korea  2021/03/08 12:30:00 GlobeNewswire
GERMANTOWN, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to…
   Orgenesis Second Quarter 2020 Revenue Increases 55% Reflecting Progress of POCare Platform  2020/08/07 07:30:00 Benzinga
Provides update on COVID-19 therapeutic programs Reports cash and cash equivalents of $97.5 million as of June 30, 2020 GERMANTOWN, Md., Aug. 07, 2020 …
   Orgenesis partners with Educell to conduct cell-based research programs (NASDAQ:ORGS)  2020/07/14 11:06:36 Seeking Alpha
Orgenesis (NASDAQ:ORGS) has collaborated with Educell Ltd., a European cell therapy company. Under the agreement, the parties plan to conduct one or more c
   ORGS, SLNO, CDTX, BLPH, ARCT added to Indexes (NASDAQ:ORGS)  2020/06/29 12:25:02 Seeking Alpha
Orgenesis (NASDAQ:ORGS) added to the Russell 3000 Index, effective after the market open June 29. Soleno Therapeutics (NASDAQ:SLNO) added to the Russell 30

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 オ―ジェネシス ORGS Orgenesis Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)